Eversept Partners’s NovoCure NVCR Stock Holding History

Eversept Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-134,917	Closed	-$1.47M	–	139
2026 Q1	$1.47M	Buy	134,917 +13,939	+12%	+$174K	0.08%	97
2025 Q4	$1.56M	Buy	+120,978	New	+$1.55M	0.08%	93

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Eversept Partners's NVCR Position: Q2 2026 in Review

Eversept Partners sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 134,917 shares — an estimated $1.47M sold.

Eversept Partners first reported a position in NVCR in Q4 2025 and held it in 2 quarters. The position peaked at $1.56M in Q4 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Eversept Partners reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Eversept Partners sold 134,917 NovoCure shares in Q2 2026, an estimated $1.47M.
Eversept Partners first reported a position in NovoCure in Q4 2025 and held it in 2 quarters.
Eversept Partners's NovoCure position peaked at $1.56M in Q4 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.